Pharmaceutical patent landscape for cancer immunotherapy: an interview with Gilles Berger.

Dr Gilles Berger is a chemist and pharmacist with broad interest in organic and theoretical chemistry, drug discovery and design, biomedical sciences and oncology. He has worked as a Research Fellow in Brussels, Paris, Montreal and at MIT in Boston, where he has gathered hands-on experience at the interface of drug design, nanotechnologies, biology and human disease. He has been involved in project management and mentoring and has in depth experience in collaborative and multi-disciplinary projects, with a proven track record of publications in various fields, in collaboration with research groups from all around Europe, Canada and the US. In recent years, he has developed as a translational scientist, allowing the use of his complementary multi-disciplinary skills toward the advancement of fundamental projects, such as organocatalysis, theoretical chemistry or halogen bonding; as well as in applications like drug discovery, as evidenced by his numerous publications aimed at developing novel anticancer medicines and other agents. He is currently a Research Fellow of the Harvard Medical School, a Research Associate at MIT and a Fellow of the Belgian Science Foundation.